Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab effects on coronary plaque in acute myocardial infarction
NL-OMON50428Phase 3Active, not recruiting
- Sponsor
- Insel Gruppe
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis, myocardial infarction (MI) and hypercholesterolemia comparing Alirocumab plus high-intensity statin with Placebo plus high-intensity statin (2 arms). Primary endpoint: Change in percent atheroma volume. Started Jul 2018; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON50428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50428.